Reversing Resistance to Targeted Therapy

References

• Hellerstedt BA, Pienta KJ. The current state of hormo-nal therapy for prostate cancer. CA Can J Clin 2002; 3: 154–79.
   Web of Science ®Google Scholar
• O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004; 12: 2317-25.
   Google Scholar
• Chen CD, Welsbie DS, Tran C, et al. Molecular deter-minants of response to antiandrogen therapy. Nature Med 2004; 10: 33–9.
   PubMed Web of Science ®Google Scholar
• Taplin M-E, Bubley GJ, Shuster D, et al. Mutations of the androgen-receptor gene in metastatic androgen indepen-dent prostate cancer. N Engl J Med 1995; 332: 1393–98.
   PubMed Web of Science ®Google Scholar
• Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 6: 1025-33.
   Google Scholar
• Craft N, Shostak Y, Carey M, Sawyers CL. A mechani-sm for hormone-independent prostate cancer through modula-tion of androgen receptor signaling by the HER-2/neu tyrosi-ne kinase. Nature Med 1999; 3: 264–5.
   Google Scholar
• Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 1999; 17: 2755-61.
   Google Scholar
• Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 20: 5474–8.
   Google Scholar
• Rahman M, Miyamoto H, Chang C. Androgen receptor coregulators in prostate cancer: mechanisms and clinical impli-cations. Clin Cancer Res 2004; 7: 2208–19.
   Web of Science ®Google Scholar
• Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action resistance. Pharmacol Rev 2001; 1: 25–71.
   Google Scholar
• Fuqua SAW, Wiltschke C, Zhang QX et al. A Hypersensitive Estrogen Receptor- alpha mutation in premali-gnant Breast Lesions. Cancer Res 2000; 60: 4026–29.
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Hutchenson IR, Harper ME, et al. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Can 2001; 3: 175–82.
   Web of Science ®Google Scholar
• Gutteridge E, Gee JM, Nicholson RI, Robertson JFR. Biological markers associated with response to gefinitib in patients with breast cancer. Proc Am Soc Clin Oncol 2004; 23: 38.
   Google Scholar
• Robertson JFR, Gutteridge E, Cheung KL, et al. Gefitinib is active in acquired tamoxif en (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast can-cer: Results from a phase II study. Proc Am Soc Clin Oncol 2003; 22: 7.
   PubMed Web of Science ®Google Scholar
• Johnston SR, Hickish T, Ellis P, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the far-nesyl transferase inhibitor, R115777, in advanced breast can-cer. J Clin Oncol 2003; 13: 2492–9.
   Web of Science ®Google Scholar
• Baselga J, Fumaleu P, Gil M, et al. Phase II, 3-arm study of CCI-779 in combination with letrozol in postmeno-pausal women with locally advanced or metastatic breast can-cer. Proc Am Soc Clin Oncol 2004; 23: 13.
   Web of Science ®Google Scholar
• Miller KD. The Role of ErbB inhibitors in trastuzumab resistance. Oncologist 2004; 9: 16–19.
   PubMed Web of Science ®Google Scholar
• Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastu-zumab (Herceptin). J Nati Cancer Inst 2001; 93: 1852–7.
   PubMed Web of Science ®Google Scholar
• Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27141 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells. Cancer Res 2004; 64: 3981-3986.
   Google Scholar
• Rothenberg ML, Lafleur B, Washington MK, et al. Changes in epidermal growth factor receptor signaling in serum and tumour biopsies obtained from patients with pro-gressive metastatic colorectal cancer treated with gefitinib: An Eastern Cooperative Oncology Group Study. Proc Am Soc Clin Onc 2004; 23: 195.
   Google Scholar
• Saltz L, Kies M, Abbruzzese JL, Azarnia N, Needle M. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple mali-gnancies. Proc Am Soc Clin Oncol 2003; 22: 204.
   Web of Science ®Google Scholar
• Blencke S, Ullrich A, Henrik Daub. Mutation of threo-nine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem 2003; 17: 15435-40.
   Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating muta-tions in the EGFR underlying responsiveness of NSCLC to Gefitinib. N Engl J Med 2004; 21: 2129–39.
   Google Scholar
• Li B, Chang CM, Yuan M. Resistance to small molecu-le inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 2003; 21: 7443–50.
   Google Scholar
• Kantarjian HM, Talpaz M. O'Brien S et al. Dose esca-lation of imatinib mesylate can overcome resistance standard-dose therapy in patients with chronic myelogenous leukaemia. Blood 2003; 2: 473–5.
   Google Scholar
• Mahon Fx, Belloc F, Lagarde V et al. MDR1 gene ove-rexpression confers resistance to imatinib in leukaemia cell line models. Blood 2003; 101: 2368–73.
   Google Scholar
• Ferrao PT, Frost MJ, Slah SP, Ashman LK. Overexpression of P- glycoprotein in K562 cells does not con-fer resistance to the growth inhibitory effects of imatinib in vitro. Blood 2003; 102: 4499-4503.
   Google Scholar
• Gambacorti-Passerini C, Zucchetti M, Russo D, et al. Alphal acid glycoprotein binds to imatinib (5TI571) and sub-stantially alters its pharmacokinetics in chronic myeloid leuke-mia patients. Clin Cancer Res 2003; 2: 625–32
   Google Scholar
• Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (5TI571) in chronic phase and blast crisis chronic myeloid leukemia. Can Cell 2002; 2: 117–125.
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004; 5682: 399–401.
   Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 23: 4342–4349.
   Web of Science ®Google Scholar
• Gorre ME, Ellwood YK, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imati-nib mesylate-resistant chronic myeloid leukemia remain sensiti-ve to inhibitors of the BCR-ABL chaperone heat shock pro-tein 90. Blood 2002; 100: 3041-3044.
   Google Scholar
• Hoover RR, Mahon FX, Melo JV, Daley GQ. Overcoming 5TI571 resistance with the farnesyl transferase inhibitor 5CH66336. Blood 2002; 100: 1068-1071.
   Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 23: 2335–42.
   Web of Science ®Google Scholar
• Kerbel RS, Yu J, Tran J, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Can Met Rev 2001; 1-2: 79-86.
   Google Scholar
• Sweeney CJ, Miller KD, Sissons SE, et al. The antian-giogenic property of docetaxel is synergistic with a recombi-nant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagoni-zed by endothelial growth factors. Cancer Res 2001; 8: 3369-72.
   Google Scholar
• Hanada K, Perry-Lalley DM, Ohnmacht GA, Bettinotti MP, Yang JC. Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. Cancer Res 2001; 14: 5511–6.
   Google Scholar
• Pietras K, Rubin K, Sjoblom T, et al. Inhibition of PDGF signalling in tumour stroma enhances antitumour effect of chemotherapy. Cancer Res 2002; 62: 5476–84.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus I in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 4: 337–45.
   Web of Science ®Google Scholar
• Workman P. Overview: translating Hsp90 biology into Hsp90 drugs. Curr Cancer Drug Targets 2003; 5: 297–300.
   Web of Science ®Google Scholar
• Ratain M, Flaherty KT, Stadler WM, et al. Preliminary antitumour activity of BAY- 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomised discontinuation trial (RDT). Proc Am Soc Clin Onc 2004; 23: 381.
   Google Scholar
• Hainsworth JD, Sosman JA, Spiegel DR, et al. Phase II trial of bevacizumab and erlontinib in patients with metasta-tic renal carcinoma (RCC). Proc Am Soc Clin Onc 2004; 23: 381.
   Google Scholar
• de Bono JS, Tolcher AW, Rowinsky EK. The future of cytotoxic therapy: selective cytotoxicity based on biology is the key. Breast Cancer Res 2003; 3: 154–9.
   Web of Science ®Google Scholar